Novel insights into osteogenesis and matrix remodelling associated with calcific uraemic arteriolopathy

Nephrology Dialysis Transplantation

Volumn 28, Issue 4, 2013, Pages 856-868

  Kramann, Rafael ^a   Brandenburg, Vincent M ^a   Schurgers, Leon J ^b   Ketteler, Markus ^c   Westphal, Saskia ^a   Leisten, Isabelle ^a   Bovi, Manfred ^a   Jahnen Dechent, Willi ^a   Knüchel, Ruth ^a   Floege, Jürgen ^a   Schneider, Rebekka K ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c KLINIKUM COBURG   (Germany)

Author keywords

bone morphogenic protein 2; calciphylaxis; matrix Gla protein; matrix remodelling; sclerostin

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; CALCIUM; CD31 ANTIGEN; COLLAGEN TYPE 1; FIBRONECTIN; HYDROXYAPATITE; LAMININ; OSTEOCALCIN; OSTEOPONTIN; PHOSPHATE; SCLEROSTIN; TRANSCRIPTION FACTOR RUNX2;

ADULT; AGED; ARTICLE; BLOOD VESSEL CALCIFICATION; BONE DEVELOPMENT; CALCINOSIS; CELL AGGREGATION; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIUM CELL; ENERGY DISPERSIVE X RAY SPECTROSCOPY; EXTRACELLULAR MATRIX; FEMALE; HEMODIALYSIS PATIENT; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NECROSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCANNING ELECTRON MICROSCOPY; SKIN DEFECT; SPECTROSCOPY; SUBCUTANEOUS FAT; UPREGULATION;

ADULT; AGED; APOPTOSIS; BLOTTING, WESTERN; CALCIPHYLAXIS; CALCIUM; CASE-CONTROL STUDIES; CELL PROLIFERATION; CELL SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OSTEOGENESIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN DISEASES; UREMIA; YOUNG ADULT;

EID: 84875993926     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs466     Document Type: Article

References (56)

1. Brandenburg VM, Cozzolino M, Ketteler M. Calciphylaxis: a still unmet challenge. J Nephrol 2011; 24: 142-148
2. Rogers NM, Coates PT. Calcific uraemic arteriolopathy: an update. Curr Opin Nephrol Hypertens 2008; 17: 629-634
3. Selye H, Grasso S, Dieudonne JM. On the role of adjuvants in calciphylaxis. Rev Allergy 1961; 15: 461-465
4. Anderson DC, Stewart WK, Piercy DM. Calcifying panniculitis with fat and skin necrosis in a case of uraemia with autonomous hyperparathyroidism. Lancet 1968; 2: 323-325
5. Coates T, Kirkland GS, Dymock RB et al. Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis 1998; 32: 384-391 (Pubitemid 28411210)
6. Hayden MR, Goldsmith D, Sowers JR, Khanna R. Calciphylaxis: calcific uremic arteriolopathy and the emerging role of sodium thiosulfate. Int Urol Nephrol 2008; 40: 443-451
7. Don BR, Chin AI. A strategy for the treatment of calcific uremic arteriolopathy (calciphylaxis) employing a combination of therapies. Clin Nephrol 2003; 59: 463-470 (Pubitemid 36722329)
8. Singh RP, Derendorf H, Ross EA. Simulation-based sodium thiosulfate dosing strategies for the treatment of calciphylaxis. Clin J Am Soc Nephrol 2011; 6: 1155-1159
9. Sowers KM, Hayden MR. Calcific uremic arteriolopathy: pathophysiology, reactive oxygen species and therapeutic approaches. Oxid Med Cell Longev 2010; 3: 109-121
10. Hruska KA, Mathew S, Saab G. Bone morphogenetic proteins in vascular calcification. Circ Res 2005; 97: 105-114 (Pubitemid 41033466)
11. Zebboudj AF, Imura M, Bostrom K. Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J Biol Chem 2002; 277: 4388-4394 (Pubitemid 34968705)
12. Wallin R, Schurgers L, Wajih N. Effects of the blood coagulation vitamin K as an inhibitor of arterial calcification. Thromb Res 2008; 122: 411-417
13. Schurgers LJ, Cranenburg EC, Vermeer C. Matrix Gla-protein: the calcification inhibitor in need of vitamin K. Thromb Haemost 2008; 100: 593-603
14. Chatrou ML, Winckers K, Hackeng TM, Reutelingsperger CP, Schurgers LJ. Vascular calcification: the price to pay for anticoagulation therapy with vitamin K-antagonists. Blood Rev 2012; 26: 155-166
15. Hayashi M, Takamatsu I, Kanno Y et al. A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant 2012; 27: 1580-1584
16. Johnson RC, Leopold JA, Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res 2006; 99: 1044-1059 (Pubitemid 44729928)
17. Xiao G, Jiang D, Ge C et al. Cooperative interactions between activating transcription factor 4 and Runx2/Cbfa1 stimulate osteoblast-specific osteocalcin gene expression. J Biol Chem 2005; 280: 30689-30696 (Pubitemid 41291797)
18. van Bezooijen RL, Papapoulos SE, Lowik CW. Bone morphogenetic proteins and their antagonists: the sclerostin paradigm. J Endocrinol Invest 2005; 28: 15-17
19. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011; 377: 1276-1287
20. Ahmed S, O'Neill KD, Hood AF, Evan AP, Moe SM. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Am J Kidney Dis 2001; 37: 1267-1276 (Pubitemid 32525165)
21. Adiguzel E, Ahmad PJ, Franco C, Bendeck MP. Collagens in the progression and complications of atherosclerosis. Vasc Med 2009; 14: 73-89
22. Watson KE, Parhami F, Shin V, Demer LL. Fibronectin and collagen I matrixes promote calcification of vascular cells in vitro, whereas collagen IV matrix is inhibitory. Arterioscler Thromb Vasc Biol 1998; 18: 1964-1971 (Pubitemid 28565761)
23. Kramann R, Couson SK, Neuss S et al. Exposure to uremic serum induces a procalcific phenotype in human mesenchymal stem cells. Arterioscler Thromb Vasc Biol 2011; 31: e45-54
24. Schurgers LJ, Teunissen KJ, Knapen MH et al. Novel conformation-specific antibodies against matrix gamma-carboxyglutamic acid (Gla) protein: undercarboxylated matrix Gla protein as marker for vascular calcification. Arterioscler Thromb Vasc Biol 2005; 25: 1629-1633 (Pubitemid 41098932)
25. Amann K, Kronenberg G, Gehlen F et al. Cardiac remodelling in experimental renal failure-an immunohistochemical study. Nephrol Dial Transplant 1998; 13: 1958-1966 (Pubitemid 28356759)
26. Koleganova N, Piecha G, Ritz E et al. Arterial calcification in patients with chronic kidney disease. Nephrol Dial Transplant 2009; 24: 2488-2496
27. Akat K, Borggrefe M, Kaden JJ. Aortic valve calcification: basic science to clinical practice. Heart 2009; 95: 616-623
28. Janigan DT, Hirsch DJ, Klassen GA, MacDonald AS. Calcified subcutaneous arterioles with infarcts of the subcutis and skin ('calciphylaxis') in chronic renal failure. Am J Kidney Dis 2000; 35: 588-597 (Pubitemid 30185501)
29. Farah M, Crawford RI, Levin A, Chan Yan C. Calciphylaxis in the current era: emerging 'ironic' features? Nephrol Dial Transplant 2011; 26: 191-195
30. Amuluru L, High W, Hiatt KM et al. Metal deposition in calcific uremic arteriolopathy. J Am Acad Dermatol 2009; 61: 73-79
31. Csiszar A, Smith KE, Koller A et al. Regulation of bone morphogenetic protein-2 expression in endothelial cells: role of nuclear factor-kappaB activation by tumor necrosis factor-alpha, H2O2, and high intravascular pressure. Circulation 2005; 111: 2364-2372 (Pubitemid 40655331)
32. Fukui N, Ikeda Y, Ohnuki T et al. Pro-inflammatory cytokine tumor necrosis factor-alpha induces bone morphogenetic protein-2 in chondrocytes via mRNA stabilization and transcriptional up-regulation. J Biol Chem 2006; 281: 27229-27241 (Pubitemid 44401752)
33. Csiszar A, Ahmad M, Smith KE et al. Bone morphogenetic protein-2 induces proinflammatory endothelial phenotype. Am J Pathol 2006; 168: 629-638 (Pubitemid 43271160)
34. Bostrom KI, Rajamannan NM, Towler DA. The regulation of valvular and vascular sclerosis by osteogenic morphogens. Circ Res 2011; 109: 564-577
35. Griethe W, Schmitt R, Jurgensen JS et al. Bone morphogenic protein-4 expression in vascular lesions of calciphylaxis. J Nephrol 2003; 16: 728-732 (Pubitemid 38714259)
36. Bostrom K, Watson KE, Horn S et al. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 1993; 91: 1800-1809 (Pubitemid 23127387)
37. Dhore CR, Cleutjens JP, Lutgens E et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001; 21: 1998-2003 (Pubitemid 34219753)
38. Cohen MM, Jr. The new bone biology: pathologic, molecular, and clinical correlates. Am J Med Genet A 2006; 140: 2646-2706 (Pubitemid 44865095)
39. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997; 89: 747-754 (Pubitemid 27516177)
40. Pai AS, Giachelli CM. Matrix remodeling in vascular calcification associated with chronic kidney disease. J Am Soc Nephrol 2010; 21: 1637-1640
41. Morikawa S, Mabuchi Y, Kubota Y et al. Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. J Exp Med 2009; 206: 2483-2496
42. Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell 2008; 2: 313-319 (Pubitemid 351467394)
43. Hamill KJ, Kligys K, Hopkinson SB, Jones JC. Laminin deposition in the extracellular matrix: a complex picture emerges. J Cell Sci 2009; 122: 4409-4417
44. US Renal Data System: USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, 2008
45. Clarke B. Normal bone anatomy and physiology. Clin J Am Soc Nephrol 2008; 3(Suppl 3): S131-S139
46. Bigi A, Cojazzi G, Panzavolta S et al. Chemical and structural characterization of the mineral phase from cortical and trabecular bone. J Inorg Biochem 1997; 68: 45-51 (Pubitemid 27400550)
47. Joschek S, Nies B, Krotz R, Goferich A. Chemical and physicochemical characterization of porous hydroxyapatite ceramics made of natural bone. Biomaterials 2000; 21: 1645-1658 (Pubitemid 30347307)
48. Schlieper G, Aretz A, Verberckmoes SC et al. Ultrastructural analysis of vascular calcifications in uremia. J Am Soc Nephrol 2010; 21: 689-696
49. Contiguglia SR, Alfrey AC, Miller NL, Runnells DE, Le Geros RZ. Nature of soft tissue calcification in uremia. Kidney Int 1973; 4: 229-235
50. Moester MJ, Papapoulos SE, Lowik CW, van Bezooijen RL. Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 2010; 87: 99-107
51. Baron R, Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007; 148: 2635-2643 (Pubitemid 46984775)
52. Drueke TB, Lafage-Proust MH. Sclerostin: just one more player in renal bone disease? Clin J Am Soc Nephrol 2011; 6: 700-703
53. Cejka D, Herberth J, Branscum AJ et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 2011; 6: 877-882
54. Zhu D, Mackenzie NC, Millan JL, Farquharson C, MacRae VE. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One 2011; 6: e19595.
55. Didangelos A, Yin X, Mandal K et al. Proteomics characterization of extracellular space components in the human aorta. Mol Cell Proteomics 2010; 9: 2048-2062
56. Sorescu GP, Song H, Tressel SL et al. Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress induces monocyte adhesion by stimulating reactive oxygen species production from a nox1-based NADPH oxidase. Circ Res 2004; 95: 773-779 (Pubitemid 39390579)